QSAR and Drug Design

Part 1 Three-dimensional structure-based drug design, molecular modelling and three-dimensional QSAR: rational approaches to computer drug design based on drug-receptor interactions, A. Itai et al; drug design based on receptor modelling using a system "BIOCES(E)", K. Akahane and H. Umeyama; mechanisms of the selective inhibition of thrombin, factor Xa, plasmin and trypsin, T. Masuzaki et al; three-dimensional structure-activity relationships and receptor mapping of quinolone antibacterials, H. Koga and M. Ohta; classical and three-dimensional quantitative structure-activity analyses of steroid hormones - structure-receptor binding patterns of anti-hormonal drug candidates, M. Yamakawa et al. Part 2 Quantitative structure-parameter analyses and database-oriented and newer statistical (Q)SAR procedures and drug design: analysis and prediction of 1-octano/water partition coefficients of substituted diazines with substituent and structural parameters, C. Yamagami et al; hydrophobicities of Di-to pentapeptides having unionizable side chains and correlation with substituent and structural parameters, M. Akamatsu and T. Fujita; analysis of amino acid sequence-function relationships in proteins, T. Nishioka and J. Oda; background and features of EMIL, a system for database-aided bioanalogous structural transformation of bioactive compounds, T. Fujita et al; fuzzy adaptive least squares and its use in quantitative structure-activity relationships, I. Moriguchi and S. Hirono. Part 3 Traditional QSAR and drug design: structure-activity relationships in medicinal chemistry - development of drug candidates from lead compounds, Z.R. Guo; chemical modification and structure-activity relationship studies of piperine and its analogs - an example of drug development from folk medicine, R.-I. Li and S.-Y. Wang; structural requirements of leukotriene antagonists, H. Terada et al; quantitative structure-activity relationships of a new class of Ca2+-antagonistic and alpha-blocking phenoxyalkylamine derivatives, K. Mitani; applications of quantitative structure-activity relationships to drug design of piperazine derivatives, H. Ohtaka; quantitative structure-activity studies of neurotoxic acrylamide analogs, K. Hashimoto et al.